Vaxart (NASDAQ:VXRT) Stock Passes Below 200 Day Moving Average of $0.88

Vaxart, Inc. (NASDAQ:VXRT)’s share price crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.88 and traded as low as $0.86. Vaxart shares last traded at $0.87, with a volume of 1,069,507 shares trading hands.

Wall Street Analysts Forecast Growth

Separately, B. Riley raised shares of Vaxart from a “neutral” rating to a “buy” rating and set a $2.00 price target for the company in a research note on Wednesday, January 31st.

Vaxart Stock Down 3.2 %

The company has a market cap of $150.58 million, a P/E ratio of -1.49 and a beta of 0.44. The business’s 50 day moving average is $1.18 and its 200 day moving average is $0.88.

Vaxart (NASDAQ:VXRT) last issued its quarterly earnings data on Thursday, March 14th. The biotechnology company reported ($0.12) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.03. The company had revenue of $3.25 million during the quarter, compared to the consensus estimate of $0.45 million. Vaxart had a negative net margin of 1,117.56% and a negative return on equity of 108.45%. As a group, equities research analysts forecast that Vaxart, Inc. will post -0.45 EPS for the current year.

Hedge Funds Weigh In On Vaxart

A number of large investors have recently bought and sold shares of the business. JPMorgan Chase & Co. raised its stake in Vaxart by 15.2% in the second quarter. JPMorgan Chase & Co. now owns 67,047 shares of the biotechnology company’s stock worth $235,000 after buying an additional 8,844 shares in the last quarter. IHT Wealth Management LLC grew its holdings in Vaxart by 5.3% in the first quarter. IHT Wealth Management LLC now owns 258,724 shares of the biotechnology company’s stock worth $1,304,000 after purchasing an additional 13,073 shares during the last quarter. Two Sigma Advisers LP purchased a new position in Vaxart in the third quarter worth $34,000. BNP Paribas Arbitrage SA grew its holdings in Vaxart by 165.2% in the second quarter. BNP Paribas Arbitrage SA now owns 25,643 shares of the biotechnology company’s stock worth $90,000 after purchasing an additional 15,974 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its holdings in Vaxart by 1.8% in the first quarter. Charles Schwab Investment Management Inc. now owns 993,223 shares of the biotechnology company’s stock worth $752,000 after purchasing an additional 18,038 shares during the last quarter. Institutional investors own 18.05% of the company’s stock.

Vaxart Company Profile

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical dysplasia.